{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T01:17:18Z","timestamp":1718414238845},"reference-count":33,"publisher":"Japan Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2007]]},"DOI":"10.1507\/endocrj.k06-208","type":"journal-article","created":{"date-parts":[[2008,2,26]],"date-time":"2008-02-26T01:48:17Z","timestamp":1203990497000},"page":"855-862","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Significance of 1-year Treatment with Raloxifene on Bone and Lipid Metabolism in Japanese Postmenopausal Women with Osteoporosis"],"prefix":"10.1507","volume":"54","author":[{"given":"Takafumi","family":"MAJIMA","sequence":"first","affiliation":[{"name":"Division of Metabolic Research, Clinical Research Institute, Center for Endocrine and Metabolic Diseases, National Hospital Organization, Kyoto Medical Center"},{"name":"Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine"},{"name":"Department of General Medicine, Rakuwakai Otowa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasato","family":"KOMATSU","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"SHIMATSU","sequence":"additional","affiliation":[{"name":"Division of Metabolic Research, Clinical Research Institute, Center for Endocrine and Metabolic Diseases, National Hospital Organization, Kyoto Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"SATOH","sequence":"additional","affiliation":[{"name":"Division of Metabolic Research, Clinical Research Institute, Center for Endocrine and Metabolic Diseases, National Hospital Organization, Kyoto Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"FUKAO","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Medicine, Rakuwakai Otowa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"NINOMIYA","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Rakuwakai Otowa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"MATSUMURA","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Rakuwakai Otowa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuwa","family":"NAKAO","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.637"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647.","DOI":"10.1056\/NEJM199712043372301"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H 3rd, Gennari C, Christiansen C, Arnaud CD, Delmas PD (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160: 3444-3450.","DOI":"10.1001\/archinte.160.22.3444"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW (1999) Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 10: 330-336.","DOI":"10.1007\/s001980050236"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1424-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kung AW, Chao HT, Huang KE, Need AG, Taechakraichana N, Loh FH, Gonzaga F, Sriram U, Ismail NM, Farooqi A, Rachman IA, Crans GG, Wong M, Thiebaud D (2003) Efficacy and safety of raloxifene 60 milligrams\/day in postmenopausal Asian women. J Clin Endocrinol Metab 88: 3130-3136.","DOI":"10.1210\/jc.2002-021855"},{"key":"7","unstructured":"7. Johnell O, Kanis JA, Sarkar S, Wu W, De Laet C, Oden A, Pavo I (2001) Relationship between age and prior use of HRT and vertebral fracture risk reduction with raloxifene in postmenopausal women: Results from the MORE trial. J Bone Miner Res 16: S1; S414."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Johnell O, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, Zhou C, Pavo I (2004) Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 19: 764-772.","DOI":"10.1359\/jbmr.040211"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1007\/BF00305521"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Francis RM, Boyle IT, Moniz C, Sutcliffe AM, Davis BS, Beastall GH, Cowan RA, Downes N (1996) A comparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos Int 6: 284-290.","DOI":"10.1007\/BF01623386"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E (2000) Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 15: 770-779.","DOI":"10.1359\/jbmr.2000.15.4.770"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.4.622"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-005-0073-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Richy F, Ethgen O, Bruyere O, Reginster JY (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15: 301-310.","DOI":"10.1007\/s00198-003-1570-5"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.89.255"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E (2002) Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87: 985-992.","DOI":"10.1210\/jcem.87.3.8325"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.1.1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19: 394-401.","DOI":"10.1359\/JBMR.0301243"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Uusi-Rasi K, Beck TJ, Semanick LM, Daphtary MM, Crans GG, Desaiah D, Harper KD (2006) Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 17: 575-586.","DOI":"10.1007\/s00198-005-0028-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR; Continuing Outcomes Relevant to Evista (CORE) Investigators (2005) Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20: 1514-1524.","DOI":"10.1359\/JBMR.050509"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2006) Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 17: 313-316.","DOI":"10.1007\/s00198-005-2030-1"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12: 922-930.","DOI":"10.1007\/s001980170020"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Delmas PD (2000) Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11: S6;S66-S76.","DOI":"10.1007\/s001980070007"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ott SM, Oleksik A, Lu Y, Harper K, Lips P (2002) Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 17: 341-348.","DOI":"10.1359\/jbmr.2002.17.2.341"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.4.613"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Burr D (2003) Microdamage and bone strength. Osteoporos Int 14: S5; S67-S72.","DOI":"10.1007\/s00198-003-1476-2"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.10.3425"},{"issue":"2","key":"28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1507\/endocrj.49.211","volume":"49","author":"YAMAGUCHI T","year":"2002","ISSN":"http:\/\/id.crossref.org\/issn\/0918-8959","issn-type":"print"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Koshiyama H, Wada Y, Nakamura Y (2001) Hypercholesterolemia as a possible risk factor for osteopenia in type 2 diabetes mellitus. Arch Intern Med 161: 1678.","DOI":"10.1001\/archinte.161.13.1678"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Pennisi P, Signorelli SS, Riccobene S, Celotta G, Di Pino L, La Malfa T, Fiore CE (2004) Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 15: 389-395.","DOI":"10.1007\/s00198-003-1550-9"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1786-z"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200201089"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Parhami F, Tintut Y, Beamer WG, Gharavi N, Goodman W, Demer LL (2001) Atherogenic high-fat diet reduces bone mineralization in mice. J Bone Miner Res 16: 182-188.","DOI":"10.1359\/jbmr.2001.16.1.182"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/54\/6\/54_K06-208\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:44:44Z","timestamp":1618296284000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/54\/6\/54_K06-208\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.k06-208","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007]]}}}